Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Brandau
Sven
S
D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D015232:Dinoprostone / Q000276:immunology / Q000652:urine; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome; D015854:Up-Regulation; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib; D015232:Dinoprostone